Patents by Inventor Albrecht Stoffler

Albrecht Stoffler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NERAMEXANE FOR THE TREATMENT OF NYSTAGMUS
    Publication number: 20100234358
    Abstract: The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate.
    Type: Application
    Filed: June 6, 2008
    Publication date: September 16, 2010
    Applicant: MERZ PHARMA GMBH & CO. KGAA
    Inventors: Angelika Hanschmann, Michael Althaus, Albrecht Stoffler
  • Memantine For The Treatment Of Mild And Mild To Moderate Alzheimer's Disease
    Publication number: 20100048726
    Abstract: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjects with mild, or mild-to-moderate Alzheimer's disease.
    Type: Application
    Filed: October 29, 2009
    Publication date: February 25, 2010
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Scott McDonald, Ivan Gergel, Steven Potkin, Albrecht Stöffler, Yvonne Wirth, Hans-Joerg Moebius
  • Memantine for the treatment of mild and mild to moderate Alzheimer's disease
    Publication number: 20060020042
    Abstract: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjectes with mild, or mild-to-moderate Alzheimer's disease.
    Type: Application
    Filed: January 5, 2005
    Publication date: January 26, 2006
    Applicant: Forest Laboratories, Inc.
    Inventors: Scott McDonald, Ivan Gergel, Steven Potkin, Albrecht Stoffler, Yvonne Wirth, Hans-Joerg Moebius
  • 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
    Publication number: 20050203191
    Abstract: The present invention relates to the treatment of behavioral disorders, especially agitation, associated with a central nervous system (CNS) disorder, especially Alzheimer's disease (AD), cerebrovascular disease (VaD), or Down's Syndrome, in a mammal, comprising administering to said mammal an 1-aminocyclohexane, alone or in combination with a acetylcholinesterase inhibitor. In one embodiment, the 1-aminocyclohexane is memantine.
    Type: Application
    Filed: March 3, 2005
    Publication date: September 15, 2005
    Applicant: Forest Laboratories, Inc.
    Inventors: Scott McDonald, Barry Reisberg, Steven Ferris, Hans-Joerg Moebius, Albrecht Stoffler